The Medicines Patent Pool has signed agreements with nine patent holders for thirteen HIV antiretrovirals, one HIV technology platform, a tuberculosis treatment and three hepatitis C direct-acting antivirals. 24 generic manufacturers and product developers have now signed MPP sublicensing agreements.
The recent presentation above is highlighting the progress of generic partners in developing MPP-licensed medicines. It provides an overview of manufacturer filing timelines per combination, countrywide filing status and plans for registration, as well as the latest impact data from MPP’s agreements. Generic competition is making a difference in fostering lower prices and improving treatment coverage. Generic partners have distributed 17 million patient years of HIV and hepatitis C products, saving international procurers USD553 million (Jan. 2012-December 2017).